Patrick Roche - HTG Molecular President
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
President
Dr. Patrick C. Roche, Ph.D., is Senior Vice President Research and Product Development of the Company. Dr. Roche joined us from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of RTD, where he worked for 12 years and held a number of positions of increasing responsibility, including Vice President, Head Biomarker Strategy, Translational Diagnostics, from August 2009 to April 2014, and Vice President, Assay Development and Clinical Studies, from March 2007 to July 2009. In these roles, Dr. Roche was responsible for interfacing with pharmaceutical partners in their development of targeted cancer therapeutics and facilitating the transition of biomarkers into companion diagnostics and for leading reagent product development and launching over 30 in vitro diagnostic products, including the FDAapproved ckit and HER2 tests. Prior to working at Ventana, Dr. Roche was at the Mayo Clinic Rochester, a medical research group, where he served as Director of the Immunohistochemistry Laboratory and as Associate Professor of Laboratory Medicine and Pathology. Dr. Roche has coauthored more than 125 peerreviewed publications and is an inventor on a number of patent filings and two issued U.S. patents since 2014.
| Age | 70 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 877 289 2615 |
| Web | https://www.htgmolecular.com |
HTG Molecular Management Efficiency
The company has return on total asset (ROA) of (0.6226) % which means that it has lost $0.6226 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4321) %, meaning that it created substantial loss on money invested by shareholders. HTG Molecular's management efficiency ratios could be used to measure how well HTG Molecular manages its routine affairs as well as how well it operates its assets and liabilities.HTG Molecular Diagnostics currently holds 4.83 M in liabilities with Debt to Equity (D/E) ratio of 2.52, implying the company greatly relies on financing operations through barrowing. HTG Molecular Diagnostics has a current ratio of 1.86, which is within standard range for the sector. Note, when we think about HTG Molecular's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Alec Barclay | T2 Biosystms | 44 | |
Management Performance
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 |
HTG Molecular Diagnostics Leadership Team
Elected by the shareholders, the HTG Molecular's board of directors comprises two types of representatives: HTG Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HTG. The board's role is to monitor HTG Molecular's management team and ensure that shareholders' interests are well served. HTG Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HTG Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laura Godlewski, Principal Accounting Officer | ||
| Shaun McMeans, CFO and VP of Fin. and Admin. | ||
| John Lubniewski, Chief Bus. Officer | ||
| Stephen Barat, VP Therapeutics | ||
| Byron Lawson, VP Officer | ||
| Debra Gordon, Vice President and Chief Legal Counsel | ||
| Patrick Roche, Senior Vice President - Research and Product Development |
HTG Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HTG Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |